DDInter690 DDInter239
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.
Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 .
Ethanol {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Diphenhydramine
Diphenhydramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brivaracetam
Ethanol {u} (Compound) binds {v} (Gene) CYP4A11
CYP4A11 {u} (Gene) is bound by {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brivaracetam
Ethanol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Abiraterone
Abiraterone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brivaracetam
Ethanol (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Diphenhydramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Ethanol (Compound) binds CYP4A11 (Gene) and CYP4A11 (Gene) is bound by Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Ethanol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Abiraterone (Compound) and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Brivaracetam